LJPC Shares Outstanding History



Below is a table of the LJPC shares outstanding history going back to 1/14/2014:

Date LJPC Shares Outstanding
1/14/20140.00B
1/29/20144.83M
3/21/20147.26M
4/29/20147.87M
8/12/201415.23M
11/7/201415.23M
2/27/201515.24M
4/23/201515.25M
7/31/201515.25M
10/31/201518.24M
2/22/201618.25M
3/31/201618.25M
4/22/201618.25M
7/31/201618.25M
10/31/201618.25M
3/31/201722.12M
4/21/201722.12M
7/21/201722.12M
10/20/201722.15M
2/16/201822.17M
3/31/201826.15M
4/23/201826.15M
7/27/201826.23M
10/19/201826.23M
2/20/201927.08M
2/28/201927.08M
4/25/201927.10M
7/26/201927.13M
10/25/201927.16M
2/3/202027.22M
4/29/202027.30M
7/27/202027.36M
11/3/202027.38M
2/8/202127.43M
3/1/202127.44M
4/3/202127.45M
7/23/202127.49M
10/22/202127.52M
2/25/202225.96M
4/15/202225.62M
8/1/202224.94M

Also see: LJPC Market Cap History
LJPC YTD Return
LJPC Historical Shares Outstanding:
+22.49% CAGR
LJPC Historical Shares Outstanding: +22.49% CAGR

Mouse over chart for data details
1/14/2014 ...8/1/2022
La Jolla Pharmaceutical is focused on the commercialization of therapies. GIAPREZA™ (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) for injection is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections. Co. owns various product candidates that are in preclinical development including: TP-6076, an IV formulation of a synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. We show 41 historical shares outstanding datapoints in our coverage of LJPC's shares outstanding history.

Understanding the changing numbers of LJPC shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like LJPC versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching LJPC by allowing them to research LJPC shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree LJPC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
La Jolla Pharmaceutical (LJPC) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

LLY Shares Outstanding History
LMAT Shares Outstanding History
LMNX Shares Outstanding History
LNSR Shares Outstanding History
LNTH Shares Outstanding History
LOGC Shares Outstanding History
LOXO Shares Outstanding History
LPCN Shares Outstanding History
LPNT Shares Outstanding History
LPTX Shares Outstanding History
More Healthcare companies »

 

LJPC Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.